KMO inhibitor (Sumitomo Dainippon Pharma)

N/A

Report date: 2025/01/26 17:35:52
NME

Base Information

Drug NameKMO inhibitor (Sumitomo Dainippon Pharma)
Drug Alias Namekynurenine monooxygenase inhibitor (Sumitomo Dainippon Pharma)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionKynurenine 3-monooxygenase inhibitors
TargetsKynurenine 3-monooxygenase
Therapy Area/IndicationsHuntington Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryJapan
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesSumitomo Pharmaceuticals Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSumitomo Pharmaceuticals Co Ltd
Inactive CompaniesN/A
Active IndicationsHuntington Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A